BIOSYNTAGMA, LLC

Medtech

Microfluidic platform that combines spatial imaging of tissue with laser-based cell isolation and multi-omic analysis

biosyntagma.com →
Grants
$1.5M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
1 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: High multiplex visual mapping of heterogeneity in FFPE biospecimen$213,904
Federal grantNational Science Foundation · Phase II · SBIR Phase II: High multiplex visual mapping of heterogeneity in FFPE biospecimen$892,086
Federal grantDepartment of Health and Human Services · Phase I · Novel method for spatial, multi-omic visualization of single-cell heterogeneity$196,129
Federal grantDepartment of Health and Human Services · Phase I · Novel method for spatial, multi-omicvisualization of single-cell heterogeneity$198,129
Federal grantDepartment of Health and Human Services · Phase I · Novel method for spatial, multi-omic visualization of single-cell heterogeneity$2,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1922Innoventric——
1923RAPHA ROBOTICS INC——
1924IN VIVO MICROSYSTEMS TECHNOLOGIES, LLC——
1925BIOSYNTAGMA, LLC——
1926WEARABLE DEFENSE LLC——
1927SEER, INC.——
1928ADDINEX TECHNOLOGIES, INC.—$1.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 2

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.